Cargando…
Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1(N546K) Mutation
Autores principales: | Capone, Stephen, Ketonen, Leena, Weathers, Shiao-Pei, Subbiah, Vivek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200395/ https://www.ncbi.nlm.nih.gov/pubmed/35507888 http://dx.doi.org/10.1200/PO.21.00371 |
Ejemplares similares
-
FGFR1 tyrosine kinase domain duplication in pilocytic astrocytoma with anaplasia
por: Ballester, Leomar Y., et al.
Publicado: (2018) -
KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas
por: Becker, Aline Paixão, et al.
Publicado: (2015) -
Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas
por: Lehtinen, Birgitta, et al.
Publicado: (2017) -
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
por: Lin, Qianmeng, et al.
Publicado: (2022) -
Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutation
por: Orillac, Cordelia, et al.
Publicado: (2016)